[Treatment results of intra-arterial ACNU infusion chemotherapy for primary cerebral malignant lymphoma].
From May, 1987 to January, 1991, eight patients harboring primary cerebral malignant lymphoma (primary, six cases; recurrent, two cases) were treated by intra-arterial ACNU infusion chemotherapy. All but two cases also had hyperosmotic blood brain barrier (BBB) modification. Six primary cases had conventional teletherapy of 46-58.7 Gy (average 54.1 Gy) and one recurrent case had been irradiated again by 18 Gy. The follow-up period was 3 to 67.5 months (average 21.4 months). In six cases demonstrating measurable tumors on diagnostic images, all showed a complete response. The 1- and 2-year survival time was 50.0% and 37.5%, respectively, with a median survival time of 13.0 months. These were somewhat better than our previous results, but not better than those in the literature. Although intra-arterial ACNU infusion chemotherapy with BBB modification was not considered superior to other chemotherapy regimens, it yielded some long-surviving cases. Hence this chemotherapy is still worth using for treatment of primary cerebral malignant lymphoma.
Hayashi
A
A
Dept. of Neurosurgery, Kanagawa Cancer Center.
Kyuma
Y
Y
Chiba
Y
Y
Kuwana
N
N
Kojima
Y
Y
D000328:Adult; D000368:Aged; D001812:Blood-Brain Barrier / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D015376:Nimustine / Q000008:administration & dosage* / Q000494:pharmacology; D011867:Radioisotope Teletherapy; D015996:Survival Rate
D015376:Nimustine